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Activation-Induced Cytidine Deaminase (AID)
Deficiency Causes the Autosomal Recessive Form
of the Hyper-IgM Syndrome (HIGM2)
HIGM2 patients (and in AID2/2 mice) demonstrates the
absolute requirement for AID in several crucial steps
of B cell terminal differentiation necessary for efficient
antibody responses.
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A rare human immunodeficiency, the Hyper-IgM syn-malities characterize AID deficiency: (1) the absence
drome (HIGM), is characterized by normal or elevatedof immunoglobulin class switch recombination, (2) the
serum IgM levels with absence of IgG, IgA, and IgE,
lack of immunoglobulin somatic hypermutations, and resulting in a profound susceptibility to bacterial infec-
(3) lymph node hyperplasia caused by the presence of tions (Notarangelo et al., 1992). The molecular basis of
giant germinal centers. The phenotype observed in the X-linked form (HIGM1) is due to mutations in the
gene coding for CD40L (Allen et al., 1993; Aruffo et al.,
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patients exhibit a remarkable defect in germinal center sequencing was normal and CD40L was normally ex-
pressed on activated T cells. CD40 gene sequence and/formation (Facchetti et al., 1995). These observations
emphasize the role of CD40L/CD40 interaction in the or membrane expression revealed no abnormality. Pe-
ripheral blood B cell (CD191) counts were normal. All Bterminal differentiation of B cells in secondary lymphoid
organs. In these patients, B cells are intrinsically normal cells expressed sIgM and sIgD while some CD191 B
cells from age-matched controls did not express eithersince they can be normally triggered by CD40 agonists
to CSR in vitro (Allen et al., 1993; Aruffo et al., 1993; sIgM or sIgD (data not shown). CD27, a recently identi-
fied marker of memory B cells (Klein et al., 1998) wasDurandy et al., 1993; Korthauer et al., 1993).
Another HIGM syndrome with autosomal recessive expressed on a normal proportion (from 9% to 45%)
and with the same intensity on B cells, as compared withinheritance (HIGM2) has been described (Callard et al.,
1994; Conley et al., 1994). In these patients, CD40L gene age-matched controls (Table 2 and data not shown).
In vitro activation of peripheral blood mononuclearsequencing and membrane molecule expression are
normal and, in contrast to CD40L-deficient patients, B cells (PBMC) by soluble CD40L (sCD40L) and IL-4, which
regularly induced IgE production by B cells from controlscells do not undergo CSR in vitro in the presence of
CD40-agonists. CD40 gene sequence and CD40 mole- and CD40L-deficient patients (Durandy et al., 1993), was
ineffective in the 15 tested HIGM2 patients (Table 2).cule expression are normal in these patients (Durandy
et al., 1997). A defect of other molecules involved in However, in the same culture conditions, Ie-Ce sterile
transcripts were inducible (Figure 3C). T cell (CD31) andCD40 signaling such as the TRAF proteins (Hu et al.,
1994; Cheng et al., 1995; Sato et al., 1995; Ishida et al., T cell subset numbers (CD41 and CD81) as well as in
vitro T cell proliferation to mitogens and antigens was1996a, 1996b) or proteins involved in the activation of
transcription factor NF-kB such as TANK (Cheng and normal (data not shown).
Baltimore., 1996; Rothe et al., 1996) or NIK (Malinin et
al., 1997; Song et al., 1997) have also been excluded Identification of the HIGM2 Genetic Locus
(unpublished data). In addition, activation by CD40 ago- Genetic mapping was investigated by studying the seg-
nists of monocytes and dendritic cells from these pa- regation of polymorphic microsatellite markers in 10
tients is consistently detectable (Revy et al., 1998), families (8 consanguineous) . The genome was randomly
strongly suggesting that the intrinsic defect in HIGM2 screened by using 280 polymorphic markers. We per-
patients originates in B cells, either in a B cell–specific formed homozygosity mapping in the eight consanguin-
CD40 triggered event, or in the CSR mechanism itself. eous families and performed a bipoint LOD score analy-
In order to identify the genetic basis of the HIGM2 sis in all affected families. Disease segregation was
syndrome, we performed a genome-wide search for compatible with the D12S372 marker (telomeric region
susceptibility loci using polymorphic microsatellite of short arm of chromosome 12) in the studied families.
markers in consanguineous families. We demonstrated Further analysis with additional markers was performed
a strong linkage to chromosome 12p13. As the human and two additional multiplex nonconsanguineous fami-
AID (huAID) gene, a possible candidate gene, also maps lies were included. Multipoint analysis with those addi-
to 12p13 (Muto et al., 2000), we investigated whether tional markers gave a maximum LOD score of 10.45 for
human AID gene defects could cause the HIGM2 syn- marker D12S1695 (u 5 0.00). Recombination analysis
drome. We describe 10 independent mutations in the defined the critical genetic interval on 12p13, as no re-
huAID gene in 18 patients with HIGM2 from 12 families. combination was found in all tested families between
We demonstrate that the HIGM2 syndrome is character- markers D12S397 and D12S1697, encompassing a 4.5
ized by defective CSR, defective generation of somatic cM region. Among a YAC contig covering the delineated
mutations of the Ig V genes, and by abnormal germinal region, the 943a9 YAC, which contains both D12S1695
centers, showing that AID gene expression plays a key and D12S336 markers, was shown to harbor exon 2 of
role in terminal B cell differentiation. huAID (Figure 2A).
Results Sequencing of huAID Gene in HIGM2 Patients
Because the expression of mouse AID is strictly re-
stricted to GC B cells and B cells induced to switch inPatients’ Characteristics
Eighteen patients from 12 unrelated families (Figure 1) vitro, and the huAID gene (Muto et al., 2000) and HIGM2
locus colocalize on chromosome 12p13, we studiedwere diagnosed with hyper-IgM syndrome (HIGM) de-
fined by markedly diminished serum levels of IgG and huAID as a possible candidate gene. The coding se-
quence of huAID gene, including the 5 exons and theIgA with a normal or increased serum level of IgM (Table
1). All patients presented in childhood with recurrent adjacent intronic regions, was sequenced in 18 patients.
Ten independent mutations were found (Figures 2B andbacterial sino-respiratory and gastro-intestinal tract in-
fections (Table 1). A characteristic feature observed in 2C). Five homozygous missense mutations, causing dif-
ferent amino acid substitutions, were identified in 7 con-most of the patients (13/18) was lymphoid hyperplasia,
leading to tonsillectomy in 5 of them. No opportunistic sanguineous families. The same mutation was observed
in exon 2 in patients P7, P11-P12, and P18 from 3 unre-infections occurred, in contrast to those patients with
HIGM1 (Levy et al., 1997). Anti-tetanus IgG antibodies lated families of Turkish origin. Segregation of sur-
rounding polymorphic markers clearly indicate that twowere not found despite immunization (data not shown),
while IgM isohemagglutinins, when evaluable, were de- of 3 families (families 4 and 7) have received the same
alleles, suggesting a common origin of the mutation. Intected (Table 1). From diagnosis, all patients were
treated with intravenous Ig substitution. As shown in three other Turkish families, three different point muta-
tions were found causing amino acid substitutions inFigure 1, both males (n 5 13) and females (n 5 5) were
affected. Family consanguinity was frequent (9 out of exon 3 (patients P9-P10 and P16) or exon 4 (P14-P15).
The missense mutation observed in P16 was located12), suggesting an autosomal recessive inheritance pat-
tern. HIGM1 was excluded in all, since CD40L gene within the cytidine deaminase catalytic region in exon
AID Gene Defects Cause HIGM2 Syndrome
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Figure 1. Pedigree of the HIGM2 Families
The figure depicts the pedigrees of the 12 families included in the study (9 consanguineous).
3 (Figures 2B–2D). A homozygous 19 bp deletion was substitution was detected leading to a stop codon in
the cytidine deaminase catalytic region in exon 3. Theobserved in patient P17 at the beginning of exon 2,
causing a frameshift and a premature stop codon. In the mutation was inherited from the father, who was hetero-
zygous, but was not detected in the mother. This obser-unrelated patients P6 and P8, an identical homozygous
base change leads to a stop codon in exon 4. In all these vation suggested a genomic deletion spanning exon 3
in the mother, confirmed by Southern blot analysis infamilies, parents were heterozygous for the mutation. In
family 1 (P1-P2-P3), a single homozygous nucleotide the mother and affected children (data not shown). The
Table 1. Patients’ Characteristics
Ig levels (g/l) IgM Antibody production
Age at
diagnosis Recurrent Lymphoid Hemaglutinins (titer 3 1021)
Family Origin Patients (year) infections hyperplasia IgM IgG IgA Anti-A Anti-B
1 Morocco P1 6 1 1 4.5 ,0.06 ,0.07 4 4
P2 5 1/2 1 1 ,0.06 ,0.07 32 16
P3 1 1 1 1 ,0.06 ,0.07 NE 4
2 Morocco P4 5 1 1 2.4 0.4 ,0.07 NE 64
P5 1 1/2 2 1.5 ,0.06 ,0.07 NE 64
3 Italy P6 6 1 2 8 ,0.06 ,0.07 16 8
4 Turkey P7 2 1 2 1.6 0.5 ,0.07 ND ND
5 Italy P8 2 1 1 9 0.3 ,0.07 32 4
6 Turkey P9 12 1 1 10 0.5 ,0.02 16 16
P10 5 1 1 11 0.1 ,0.02 NE 2
7 Turkey P11 13 1 1 7 ,0.06 ,0.02 512 6
P12 13 1 1 17 ,0.05 ,0.02 NE NE
8 Turkey P13 8 1 1 34 0.05 ,0.02 128 512
9 Turkey P14 3 1 1 9 0.7 0.1 1,024 512
P15 8 1 1 11 ,0.02 ,0.02 NE 128
10 Turkey P16 1 1 2 10 1.3 0.2 NE NE
11 Turkey P17 12 1 1 37 ,0.02 ,0.02 32 32
12 Turkey P18 2 1 2 5.6 ,0.02 ,0.02 ND ND
Age-matched 1–5 0.5–1.1 5–12 0.3–1.3 4–16 4–16
controls 5–13 0.6–1.7 7–15 0.8–2.3 16–128 16–128
ND 5 Not done.
NE 5 Not evaluable (because of blood group).
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Table 2. Patients’ B Cell Characteristics
In vitro induced IgE
production in presence
Percentage of Percentage of of sCD40L 1 IL-4
Patients CD191/PBMC* CD271/CD191 cells (ng/ml)**
P1 21 10 ,0.1
P2 17 21 ,0.1
P3 14 ND ,0.1
P4 16 23 ,0.1
P5 17 29 ,0.1
P6 18 ND ND
P7 20 ND 0.3
P8 18 19 ND
P9 13 14 ,0.1
P10 9 9 ,0.1
P11 14 13 ,0.1
P12 12 19 0.5
P13 14 28 ND
P14 14 5 0.4
P15 12 45 0.2
P16 15 15 0.3
P17 17 9 0.7
P18 26 21 0.3
Controls 5–25 10–47 8–24
ND 5 Not determined.
* All CD19 B cells also express CD40.
** Production of IgE in unstimulated B cells from patients and controls was always lower than 0.5 ng/ml.
same nucleotide substitution leading to a stop codon of somatic mutations in the V3-23 Ig V gene, a member
of the VH3 family expressed in 4%–10% of B cells (Stew-in exon 3 was found in patients from family 2 (P4-P5),
art et al., 1993), was analyzed. In the first set of experi-inherited from the mother. The same haplotype was
ments, the frequency of mutation of V3-23-Cm tran-common to families 1 and 2, both from Morocco. A
scripts expressed by CD191 blood B cells from patientsfurther distinct heterozygous mutation, a 9 bp deletion,
P4 and P18 was respectively 0% with 13/13 sequencesinherited from the father, and also located in the cytidine
devoid of mutations (P4) and 0.4% mutation per bp withdeaminase catalytic region, was found in these 2 pa-
5/9 sequences unmutated (P18) . These results differedtients (Figures 2B–2D).
from those obtained with a normal adult control (2%In contrast, no mutations were found in the huAID
mutation per bp) and a 2 year old control (2.5% mutationsequence in 106 normal chromosomes from unrelated
per bp).individuals.
In a second set of experiments, the mutation fre-
quency of the V3-23-Cm transcripts expressed by puri-Expression of huAID Gene
fied CD191 CD271 B cells from these two patients andExpression of the huAID gene was investigated in tonsils
three other patients were analyzed. The frequency offrom normal controls and patient P4 by RT-PCR and
V3-23 mutations from patients was significantly reducedNorthern blot analysis. HuAID mRNA was similarly de-
and ranged from 0% to 0.9% mutation per bp, as com-tected by both methods in tonsil material from P4 and
pared to 2.6% to 6.3% mutation per bp in 3 differentcontrol (Figures 3A and 3B). This was not an unexpected
age-matched controls (Table 3). Of note, in patients P2finding, given at least one of P4 mutations (Figure 2C).
and P17, all individual clones sequenced were com-Because murine AID expression has been found in B
pletely devoid of mutation. The pattern of mutations
cells induced to switch in vitro (Muramatsu et al., 1999), accumulated in the V3-23 gene in control B cells, unlike
the expression of huAID gene in control human B cells the rare mutations found in patients’ B cells, showed
was investigated following activation by a combination the major individual hotspots of mutations in CDRs pre-
of sCD40L and IL-4. HuAID transcripts, which were not viously reported (Levy et al., 1998) and reflects the pro-
detectable at day 0, were detected by RT-PCR after a cess of antigenic selection. These results clearly show
5 day culture of PBMC from controls (Figure 3C) and that the hypermutation process is profoundly defective
remained detectable after 8 and 12 days of culture (data in AID-deficient B cells.
not shown). In the same culture conditions, huAID mRNA
was either normally detected (patients P5, P6, and P17), Germinal Center B Cells in Lymphoid Organs
or weakly detected (patients P1 and P3) (Figure 3C). The of HIGM2 Patients
latter finding may be due to the likely instability of huAID Histological sections of enlarged tonsils from patients
mRNA carrying a stop codon in the first half of the mol- P1, P4, and P8 and cervical lymph nodes from patient
ecule. P4 showed identical marked follicular hyperplasia. GC
were 5 to more than 10 times larger than GC from control
Ig V Gene Somatic Mutations in HIGM2 Patients reactive lymph nodes (Figure 4A). Mantle zone and inter-
In order to investigate other possible consequences of follicular areas were present. Mantle zone B cell pheno-
type was normal (i.e., IgM1, IgD1, CD231, CD382,huAID defect in B cell differentiation, the rate and pattern
AID Gene Defects Cause HIGM2 Syndrome
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Figure 2. Localization and Genetic Analysis of huAID Mutations in HIGM2 Patients
(A) Multipoint LOD score analysis. The telomeric end of chromosome 12 is located on the left. A maximum LOD score of 10.45 was obtained
between polymorphic markers D12S397 and D12S89. Among the YAC contig, the 943a9 YAC was shown to harbor markers D12S336 and
D12S1695 and huAID exon 2.
(B) Localization of mutations in the huAID gene. Nine different mutations were found in the coding sequence (red) in 18 patients tested.
Mutations in patients P1-P2-P3, P4-P5, and P16 were localized in the cytidine deaminase catalytic region. In patients P1-P2-P3, a further
heterozygous deletion was detected by Southern blot (not shown).
(C) Mutations in the huAID gene. In 10 out of 12 families, the mutations were homozygous in patients (**), and in two families, heterozygous
mutations were found (*). Among these mutations, 7 were nucleotide substitutions causing missense mutations in 5 cases, or a stop codon
(X) in 2 others. Two other changes were nucleotide deletions leading to one missense mutation and one stop codon
(D) Alignment of the human and mouse amino acid sequences. The conserved cytidine deaminase motif is indicated by an open box. Only
nonidentical residues are indicated for mouse.
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Table 3. Mutations in V3-23-Cm Transcript Sequences from
CD191CD271 Purified B Cells
Clones Mutations
All Unmutated* Total Per bp, %
2 yr old control 10 0 172 5.9
3.5 yr old control 7 2 52 2.6
11 yr old control 10 1 182 6.3
P2 9 9 0 0
P4 8 7 3 0.1
P8 10 9 22 0.76
P17 12 12 0 0
P18 9 3 24 0.9
* Unmutated 5 #1 mutation.
Bcl-21, and Ki672) (Figure 4A, arrows, and data not
shown). Giant GC contained a normal follicular dendritic
cell network (DRC1, data not shown), and PNA1, CD381,
CD231, CD831, CD951, CD401, IgM1, Bcl22, and Ki671
B cells (Figures 4A and 4B and data not shown). Strik-
ingly, numerous GC B cells coexpressed sIgD (Figures
4A and 4B), contrasting with observations in normal
reactive GC in which GC IgD1 cells are scarcely found
(Figure 4A). The high proliferation frequency of B cells
in GC was associated with a dense network of macro-
phages filled with apoptotic bodies (Figure 4B, open
arrows) that gave the GC a starry sky appearance. A
dark zone and a lighter zone could be distinguished in
some patients’ follicles on Ki67 staining (data not
shown). However this “light zone” also contained numer-
ous cycling cells and sIgD1 cells. The phenotype and
size of the GC B cells identify them as proliferating
(Ki671) germinal founder cells (CD381, sIgM1, and
sIgD1) as described by Lebecque et al. (1997). SIgD1
and sIgM1 cells were also numerous in T cell areas
(Figure 4A). Occasional CD271 CD32 cells as well as
IgM and IgD plasma cells were found in GC and T cell
areas. Neither IgG nor IgA plasma cells were observed
(data not shown).
Discussion
HuAID Gene Mutations Cause HIGM2 Syndrome
In this study, compelling evidence is provided that muta-
tions in the coding sequence of the huAID gene are
Figure 3. Expression of huAID Transcripts
responsible for the HIGM2 syndrome. We studied 18
(A) HuAID transcripts were analyzed by RT-PCR in tonsils from a HIGM2 patients from 12 families who fulfilled the diag-
control (Ctl) and patient P4 as compared with CD19 transcripts. (2),
nostic criteria of HIGM2. Genetic studies clearly demon-no cDNA.
strated a strong linkage between the HIGM2 locus and(B) Northern blot analysis: similar amounts of huAID mRNA were
a short genetic region on chromosome 12p13, whichfound in patient and control tonsils, although more CD19 mRNA
contains the human counterpart of mouse AID (Muto etwas present in the patient, in accordance with the increased number
of B cells detected by immunohistology. Loading control is shown al., 2000). Sequencing of the coding sequence of huAID
by BET gel staining (lower panel). revealed deleterious mutations in all 12 families, all along
(C) hAID, CD19, and Ie-Ce transcripts were detected by RT-PCR on the gene. Widely scattered point mutations in huAID are
RNA isolated from PBMC before (d0) in control (Ctl), or after 5 day all defective, indicating the strong structural constraint
stimulation (d5) by sCD40L and IL-4 in control (Ctl) and patients. of AID in agreement with its evolutionary conservation
The HuAID RT-PCR product found in patient P6 was smaller due to
between mouse (Muramatsu et al., 1999) and humanan exon “skipping”, leading to a deletion of 35 bp, which includes
(Muto et al., 2000). Some of the mutations are predictedthe stop codon detected on the genomic DNA and lets the transcript
to lead to truncated huAID proteins by generating stopout of frame.
codons or deletions. Several of the missense mutationsIe-Ce sterile transcripts were normally amplified in patients, although
no IgE production was obtained after 12 days (see also Table 2). were localized within the putative cytidine deaminase
As a control, CD19 transcripts were similarly amplified. catalytic region of the protein (Muto et al., 2000). Despite
the lack of an accessible experimental model to validate
the effects of the huAID gene mutations, the association
of the HIGM2 phenotype with huAID gene mutations
together with the similar phenotype observed in AID2/2
AID Gene Defects Cause HIGM2 Syndrome
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Figure 4. Immunohistological Examination of Cervical Lymph Node from Patient P4
(A) Comparison between histology and immunophenotype of P4 cervical lymph node and a control reactive lymph node. On hematoxilin-
eosin staining (magnification 325), P4 lymph node shows follicular hyperplasia with giant GC, compared with classical follicular hyperplasia,
as control, shown at the same magnification. GC B cells from patient and control express CD38 (blue staining, original magnification 350).
Anti-IgD Ab stained numerous cells in interfollicular areas, as well as mantle cells (arrow), and most of the GC B cells from the patient, but
not of control (brown staining, original magnification 3100). Bcl-2 staining indicated that most GC cells did not express Bcl-2, in contrast to
the mantle zone and interfollicular areas, a pattern similar to that observed in control (brown staining, original magnification 3100). Ki67
staining reveals that most of the GC B cells from the patient are cycling (brown staining, original magnification 3100). An identical picture
was observed in 2 other patients.
(B) Expression of IgM, IgD, Ki67, and Bcl-2 (brown staining) at higher magnification (3400) in a HIGM2 germinal center from P4. On comparable
sections, the large majority of GC B cells express IgM and Ki67, numerous GC B cells coexpress IgD, but only occasional small lymphocytes—
presumably T cells—express Bcl-2. Note the very numerous macrophages filled with apoptotic bodies (open arrows). An identical picture was
observed in 2 other patients.
mice (Muramatsu et al., 2000 [this issue of Cell]) demon- machinery (Lorenz et al., 1995; Hein et al., 1998), and
the formation of RNA:DNA complexes with R-loop struc-strates the causative role of AID gene mutations in the
disease. The phenotype observed in this group of pa- ture at the S regions (Daniels and Lieber, 1995; Tracy and
Lieber, 2000). The role of DNA-PK and the Ku70–Ku80tients was fairly homogeneous and consisted of 3 abnor-
mal features characteristic of the disease, i.e., (1) defec- recombination complex in CSR has also been clearly
demonstrated (Rolink et al., 1996; Casellas et al., 1998;tive CSR, (2) defective Ig variable region gene somatic
mutation generation, and (3) finding of enlarged GC with Manis et al., 1998), whereas RAG molecules are not
required (Lansford et al., 1998). It is likely that AID playshighly proliferating B cells.
a role downstream of the germline transcription since
we observed normal induction of sterile Ie-Ce transcriptsRole of huAID in CSR
by CD40 agonists and IL-4 in HIGM2 patients. In addi-HIGM2 is characterized by absent or very low serum
tion, activation-induced de novo protein synthesis isIgG and IgA while B cells are unable to undergo Ig switch
required to perform CSR (Muramatsu et al., 1999), andin vitro (Callard et al., 1994; Conley et al., 1994; Durandy
the existence of a CSR recombinase has been postu-et al., 1997), indicating that AID is involved in CSR. How-
lated (Kinoshita and Honjo., 2000). Thus AID could be,ever, the CSR mechanism is complex and not com-
if not the CSR recombinase itself, at least an essentialpletely elucidated. CSR requires germline transcription
part of the CSR complex machinery (Muramatsu et al.,(Gu et al., 1993; Jung et al., 1993; Xu et al., 1993; Zhang
et al., 1993; Bottaro et al., 1994), an efficient splicing 1999).
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Role of huAID in Ig Variable Region Gene 1997). One possible explanation for our observation is
that, in absence of functional AID, B cells are continu-Somatic Hypermutations
Peripheral B cells from HIGM2 patients, though they ously triggered to proliferate by antigen (as they nor-
mally express the BCR), as long as no successful Ignormally express CD27, carry very rare Ig V gene so-
matic mutations compared with normal controls, based variable region gene somatic mutations have occurred.
on the study of V3-23 genes in 5 cases showing that AID
is also involved in the generation of Ig V gene somatic Concluding Remarks
mutations. The precise mechanism responsible for so- The observed consequences of AID deficiency in humans
matic mutations is not well understood. The Ig genes together with the phenotype described in the AID2/2
have to be transcriptionally active to undergo somatic mouse (Muramatsu et al., 2000 [this issue of Cell])
mutations (Peters and Storb, 1996; Fukita et al., 1998). clearly demonstrate a crucial role of AID in Ig switch, Ig
It has been suggested that the DNA mismatch repair variable region gene somatic mutation generation, and
system, as well as a newly described DNA polymerase normal germinal center formation. HuAID function, al-
(Pol m) are involved in somatic mutation generation (Cas- though unidentified, appears to be a key element con-
calho et al., 1998; Wiesendanger et al., 1998; Dominguez trolling the steps required for terminal B cell differentia-
et al., 2000). tion. These data will enable further molecular delineation
The role of AID in the generation of somatic hypermu- of the mechanisms required for B cell terminal matura-
tations is also unknown. Since CSR and somatic muta- tion and efficient antibody responses.
tion processes can occur independently (Kaartinen et
al., 1983; Jacob and Kelsoe, 1992; Liu et al., 1996), it Experimental Procedures
is unlikely that defective somatic mutation generation
Immunological Study of B Cellsprevents subsequent CSR in HIGM2 patients. HuAID
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-could rather act, as an RNA-editing enzyme, on one or
Hypaque density centrifugation. Immunofluorescent studies wereseveral templates generating yet unidentified factor(s)
performed by using specific antibodies: FITC or PE anti-CD19 mono-involved in CSR and/or somatic mutation generation
clonal antibodies (mAb), PE-anti-CD27 mAb from Immunotech (Mar-
(Muramatsu et al., 2000). seille, France), FITC-anti-CD40 mAb from Diaclone (Besanc¸on,
A residual level of CSR was found in a few patients France), PE-goat anti-hu IgM Ab, and FITC-goat anti-hu IgD Ab from
(for instance, patients P7, P14, and P16). Several hypoth- Caltag, (San Francisco, CA). Samples were analyzed on a FACScan
eses can account for this finding, i.e., residual AID activ- (Becton Dickinson, Mountain View, CA) (Durandy et al., 1990). In
vitro IgE switch was assessed in cultures of PBMC stimulated withity associated with missense mutations or a role for AID-
soluble CD40L, 1 mg/ml (Morris et al., 1999) (a kind gift from Im-independent factor(s) as suggested in family 9 (patients
munex, Seattle, WA) and IL-4 (100 U/ml, R&D system, Minneapolis,P14-P15) since no CSR could be detected in P15. Persis-
MN). IgE concentrations were evaluated in supernatants by ELISAtence of maternal B cells due to fetal tolerance might be
at day 12 (Durandy et al., 1997).one possible factor. Interestingly, detection of residual
CSR did not correlate with occurrence of somatic muta-
Linkage Analysis
tions as observed in patient P18. While no serum IgG and Genomic DNA was extracted from peripheral blood leukocytes with
IgA were detectable in this case, a low but significant proteinase K, sodium dodecyl sulfate, and a series of phenol-chloro-
frequency of somatic mutations was found. Genetic or form extractions. Microsatellite markers were studied using radio-
environmental factors may generate some variability as labeled primers from the Genethon collection. The FASTLINK 2.2
package was used for genetic linkage analysis (Cottingham et al.,serum IgG was detectable in patient P7 but not in P18,
1993) and the GENEHUNTER 1.1 program was used for multipointwho carries the same AID mutation. However, one can
linkage analysis (Kruglyak et al., 1995). A YAC contig was obtainedsuggest that an AID protein carrying a missense muta-
from CEPH, Paris, France (Krauter et al., 1995).tion (R24W) could still be active in one pathway, thus
implying that targets of AID in CSR and somatic hyper-
HuAID Gene Sequencingmutation differ.
The five exons of huAID were amplified by polymerase chain reaction
(PCR) using Thermal Cycler 9700 from Perkin Elmer (Norwalk, CT),
specific primers, and Taq High Fidelity (Roche Diagnostic, Mann-Role of huAID in Controlling GC B Cell Proliferation
heim, Germany).In sharp contrast to the lack of germinal centers (GC)
Primers for exon 1: 59-CATTAATTGAAGTGAGATTTTTCTGG-39in HIGM1 patients (Facchetti et al., 1995), lymphadenop-
(forward) 59-AGC ATTTGTGTGGAAAACTCTGG-39 (reverse) (1 cycleathy and tonsillar hypertrophy were frequently observed
at 948C 1 min, then 40 cycles at 948C 30 s, 548C 1 min, 688C 6in HIGM2 patients. Histological examination revealed
min). Primers for exon 2: 59- GAGTTTGAGGTACAAGTTGGACAC-39
giant GC filled with highly proliferating B cells. The pres- (forward) 59-ACAAGC TGATAATATTCTCCCCAT-39 (reverse) (1 cycle
ence within GC of numerous macrophages filled with at 948C 1 min, then 40 cycles at 948C 30 s, 548C 30 s, 728C 1 min).
apoptotic bodies indicate that intense apoptosis also Primers for exons 3, 4, 5: 59-TATCTCCTCTCTCCTAACACGCT-39
occurs. Therefore, huAID function is not involved in ei- (forward) 59- GATA CTCTCATTAGGAGGTCC-39 (reverse) (1 cycle at
948C 1 min then 40 cycles at 948C, 30 s, 548C 1 min, 728C 3 min).ther T cell–mediated nor BCR-mediated signaling events
PCR products were separated by electrophoresis and purifiedrequired for B cell proliferation or apoptosis (Garrone et
(Qiagen GmbH, Hilden, Germany). The 5 exons and adjacent intronical., 1995; Lagresle et al., 1996; Rathmell et al., 1996).
regions were sequenced with the dRhodamine dye terminator cycleStrikingly, GC proliferating B cells in HIGM2 patients
sequencing kit (ABI prism) and analyzed with the ABI prism 377express IgM, IgD, and CD38. This phenotype has pre-
genetic analyzer from Perkin Elmer.
viously been described on a small B cell subset corre-
sponding to germinal center founder cells (Lebecque et HuAID Gene Expression Study
al., 1997). Normally, these cells are thought to represent Total RNA from tonsillar tissue, unstimulated PBMC, or PBMC stimu-
a transitional stage between follicular mantle and GC B lated for 5–12 days with sCD40L (1 mg/ml) and IL-4 (100 U/ml) was
cells, at the onset of Ig variable region gene somatic extracted by disruption in guanidium thiocyanate followed by ultra-
centrifugation through a cesium chloride cushion. Pelleted RNA wasmutation and antigen-driven selection (Lebecque et al.,
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extracted with phenol chloroform and precipitated with ethanol. Aruffo, A., Farrington, M., Hollenbaugh, D., Li, X., Milatovich, A.,
Nonoyama, S., Bajorath, J., Grosmaire, L.S., Stenkamp, R., Neu-Single-strand cDNA transcription was produced with 5 mg of total
RNA, oligodT and reverse transcriptase (Superscript II, from Gibco bauer, M., et al. (1993). The CD40 ligand, gp39, is defective in acti-
vated T cells from patients with X-linked hyper-IgM syndrome. CellLife technologies, Paisley, Scotland)
RT-PCR was performed with: primers for AID: 59- GAGGCAAGAAG 72, 291–300.
ACACTCTGG-39 (forward) and 59- GTGACATTCCTGGAAGTTGC-39 Berberich, I., Shu, G., and Clark, E.A. (1994). Cross linking CD40 on
(reverse) (1 cycle at 948C 5 min, then 35 cycles at 948C 1 min; 568C B cells rapidly activates nuclear factor-kappa B. J. Immunol. 153,
1 min., 728C 2 min). 4357–4367.
Amplification of CD19 and Ie-Ce transcripts was performed (prim-
Berek, C., Berger, A., and Appel, M. (1991). Maturation of the immune
ers available if requested).
response in germinal centers. Cell 67, 1121–1129.
For Northern blot analysis, 10 mg of total mRNA from tonsils was
Bottaro, A., Lansford, R., Xu, L., Zhang, J., Rothman, P., and Alt,electrophoresed on alkaline agarose gels and transferred to charge
F.W. (1994). S region transcription per se promotes basal IgE classnylon membranes overnight. Northern blots were hybridized to the
switch recombination but additional factors regulate the efficiencyradio-labeled huAID probe, then stripped and rehybridized to the
of the process. EMBO J. 13, 665–674.radio-labeled CD19 probe as control. Radioactivity was determined
by using a phosphorimager. Callard, R.E., Smith, S.H., Herbert, J., Morgan, G., Padayachee, M.,
Lederman, S., Chess, L., Kroczek, R.A., Fanslow, W.C., and Armi-
tage, R.J. (1994). CD40 ligand (CD40L) expression and B cell functionCloning and Sequencing of V3-23-Cm Transcripts
in agammaglobulinemia with normal or elevated levels of IgM (HIM).CD191/CD271 and CD191/CD272 B cells were sorted using a FAC-
Comparison of X-linked, autosomal recessive, and non-X-linkedSTAR PLUS (Becton-Dickinson). The purity of CD191/CD271 B cells
forms of the disease, and obligate carriers. J. Immunol. 153, 3295–was greater than 99% and contamination by CD271 cells in the
3306.CD191/CD272 population was less than 1%. Total RNA extraction
and cDNA synthesis was performed as previously described (Levy Cascalho, M., Wong, J., Steinberg, C., and Wabl, M. (1998). Mis-
et al., 1998) with the following modifications: Cm A (59-GAGGCAGCT match repair co-opted by hypermutation. Science 279, 1207–1210.
CAGCAATC-39) primer was used for cDNA synthesis. PCR was per- Casellas, R., Nussenzweig, A., Wuerffel, R., Pelanda, R., Reichlin,
formed with 0.5 U of Pfu polymerase (Stratagene) and the primers: A., Suh, H., Qin, X.F., Besmer, E., Kenter, A., Rajewsky, K., and
V3-23 leader exon (59-GGCTGAGCTGGCTTTTTCTTGTGG-39) and Nussenzweig, M.C. (1998). Ku80 is required for immunoglobulin iso-
Cm B (59-TCACAGGAGACGAGGGGGAA-39) (35 cycles at 948C 45 s, type switching. EMBO J. 17, 2404–2411.
608C 1.5 min; 728C 2 min). PCR products were cloned using the TA
Cheng, G., Cleary, A.M., Ye, Z.S., Hong, D.I., Lederman, S., andcloning kit (Invitrogen) and V3-23 positive colonies were sequenced
Baltimore, D. (1995). Involvement of CRAF1, a relative of TRAF, inwith the dRhodamine dye terminator cycle sequencing kit (ABI
CD40 signaling. Science 267, 1494–1498.prism) and analyzed with the ABI prism 310 genetic analyzer.
Cheng, G., and Baltimore, D. (1996). TANK, a co-inducer with TRAF2
of TNF- and CD40L-mediated NF-kappaB activation. Genes Dev.Immunopathology of Lymph Nodes and Tonsils
10, 963–973.Immune reactive tonsils from patients P1, P4, and P8 and enlarged
cervical lymph node from P4 were surgically removed for diagnostic Clark, E.A., and Ledbetter, J.A. (1986). Activation of human B cells
purposes. Paraffin embedded sections were stained with hematein- through two distinct cell surface differentiation antigens, Bp35 and
eosin and serial cryostat, or, paraffin sections were incubated with Bp50. Proc. Natl. Acad. Sci. USA. 83, 4494–4498.
PNA (Vector Laboratories, Burlingame, CA) or mouse IgG1 antibod- Conley, M.E., Larche, M., Bonagura, V.R., Lawton, A.R., 3rd, Buckley,
ies to IgM (R1/69), IgD (IgD26), Bcl-2 (124), Ki67 (MiB1 and KI67), R.H., Fu, S.M., Coustan-Smith, E., Herrod, H.G., and Campana, D.
CD3 (UCHT1), mouse IgG2a antibodies to CD20 (L26) from DAKO, (1994). Hyper IgM syndrome associated with defective CD40-medi-
Glostrup, Denmark; mouse IgM anti follicular dendritic cells (DRC, ated B cell activation. J. Clin. Invest. 94, 1404–1409.
R4/23), and mouse IgG1 antibodies to CD38 (T16) from Immunotech
Cordell, J.L., Falini, B., Erber, W.N., Ghosh, A.K., Abdulaziz, Z., Mac-(Marseille, France) followed by a goat anti-mouse alkaline phospha-
Donald, S., Pullford, K.A., Stein, H., and Mason, D.Y. (1984). Immu-tase-conjugated or peroxidase-conjugated antibody. Fast blue
noenzymatic labelling of monoclonal antibodies using immune com-(Sigma) and DAB (Sigma) were used as substrates for alkaline phos-
plexes of alkaline phosphatase and monoclonal anti-alkalinephatase and peroxidase, respectively (Cordell et al., 1984).
phosphatase (APAAP complexes). J. Histochem. Cytochem. 32,
219–223.
Acknowledgments
Cottingham, R., Jr., Idury, R., and Schaffer, A. (1993). Faster sequen-
tial genetic linkage computations. Am. J. Hum. Genet. 53, 252–263.This work was supported by grants from the Institut National de la
Daniels, G.A., and Lieber, M.R. (1995). RNA:DNA complex formationSante´ et de la Recherche Me´dicale, Assistance Publique/Hoˆpitaux
upon transcription of immunoglobulin switch regions: implicationsde Paris (PHRC: AOM 96104), Association Franc¸aise contre les my-
for the mechanism and regulation of class switch recombination.opathies, European Biomed2 Program (PL 963007), Italian Telethon
Nucleic Acids Res. 25, 5006–5011.(grant E.668 to LDN), and Immune Deficiency Foundation (grant to
L. D. N.). P. R. was supported by a doctoral fellowship from Ministe`re DiSanto, J.P., Bonnefoy, J.Y., Gauchat, J.F., Fischer, A., and de
de l’Education Nationale, de la Recherche et de la Technologie, and Saint Basile, G. (1993). CD40 ligand mutations in x–linked immuno-
A.G. was supported by a PPP Healthcare Medical Trust Mid-Career deficiency with hyper-IgM. Nature 361, 541–543.
Award. We thank Drs. M. Debre´ and A. Deville, who take care of
Dominguez, O., Ruiz, J.F., Lain de Lera, T., Garcia-Diaz, M., Gonza-
some of the patients. We acknowledge Pr. F. Facchetti, Drs. F. Le
lez, M.A., Kirchhoff, T., Martinez-A, C., Bernad, A., and Bianco, L.
Deist, F. Rieux-Laucat, and J. P. de Villartay for helpful discussions,
(2000). DNA polymerase mu (Pol m), homologous to Tdt, could act
Mrs. F. Seltz for cell sorting experiments and Mrs. Tiouri for excellent
as a DNA mutator in eukaryotic cells. EMBO J. 19, 1731–1742.
secretarial assistance. We also thank Dr. Morris from Immunex for
Durandy, A., Thuillier, L., Forveille, M., and Fischer, A. (1990). Pheno-the kind gift of soluble CD40-ligand.
typic and functional characteristics of human newborns’ B lympho-
cytes. J. Immunol. 144, 60–65.Received May 9, 2000; revised June 15, 2000.
Durandy, A., Schiff, C., Bonnefoy, J.Y., Forveille, M., Rousset, F.,
Mazzei, G., Milili, M., and Fischer, A. (1993). Induction by anti-CD40References
antibody or soluble CD40 ligand and cytokines of IgG, IgA and
IgE production by B cells from patients with X-linked hyper IgMAllen, R.C., Armitage, R.J., Conley, M.E., Rosenblatt, H., Jenkins,
syndrome. Eur. J. Immunol. 23, 2294–2299.N.A., Copeland, N.G., Bedell, M.A., Edelhoff, S., Disteche, C.M.,
Simoneaux, K., et al. (1993). CD40 ligand gene defects responsible Durandy, A., Hivroz, C., Mazerolles, F., Schiff, C., Bernard, F., Jouan-
guy, E., Revy, P., DiSanto, J.P., Gauchat, J.F., Bonnefoy, J.Y., et al.for X-linked hyper-IgM syndrome. Science 259, 990–992.
Cell
574
(1997). Abnormal CD40-mediated activation pathway in B lympho- Korthauer, U., Graf, D., Mages, H.W., Briere, F., Padayachee, M.,
Malcolm, S., Ugazio, A.G., Notarangelo, L.D., Levinsky, R.J., andcytes from patients with hyper-IgM syndrome and normal CD40
ligand expression. J. Immunol. 158, 2576–2584. Kroczek, R.A. (1993). Defective expression of T-cell CD40 ligand
causes X-linked immunodeficiency with hyper-IgM. Nature 361,Facchetti, F., Apiani, C., Salvi, L., Levy, J., and Notarangelo, L.D.
539–541.(1995). Immunohistologic analysis of ineffective CD40–CD40 ligand
interaction in lymphoid tissues from patients with X-linked immuno- Krauter, K., Montgomery, K., Yoon, S.J., LeBlanc-Straceski, J., Re-
nault, B., Marondel, I., Herdman, V., Cupelli, L., Banks, A., Lieman,deficiency with hyper-IgM. J. Immunol. 154, 6624–6633.
J., et al. (1995). A second-generation YAC contig map of humanFukita, Y., Jacobs, H., and Rajewsky, K. (1998). Somatic hypermuta-
chromosome 12. Nature 377, 321–333.tion in the heavy chain locus correlates with transcription. Immunity
9, 105–114. Kruglyak, L., Daly, M., and Lander, E. (1995). Rapid multipoint linkage
analysis of recessive traits in nuclear families including homozygoz-Fuleihan, R., Ramesh, N., Loh, R., Jabara, H., Rosen, R.S., Chatila,
ity mapping. Am. J. Hum. Genet. 56, 519–527.T., Fu, S.M., Stamenkovic, I., and Geha, R.S. (1993). Defective ex-
pression of the CD40 ligand in X chromosome-linked immunoglobu- Kuppers, R., Zhao, M., Hansmann, M., and Rajewsky, K. (1993).
Tracing B cell development in human germinal centres by molecularlin deficiency with normal or elevated IgM. Proc. Natl. Acad. Sci.
USA 90, 2170–2173. analysis of single cells picked from histological sections. EMBO J.
12, 4955–4967.Garrone, P., Neidhardt, E.M., Garcia, E., Galibert, L., van Kooten,
C., and Banchereau, J. (1995). Fas ligation induces apoptosis of Lagresle, C., Mondiere, P., Bella, C., Krammer, P.H., and Defrance,
T. (1996). Concurrent engagement of CD40 and the antigen receptorCD40-activated human B lymphocytes. J. Exp. Med. 182, 1265–
1273. protects naive and memory human B cells from APO-1/Fas-medi-
ated apoptosis. J. Exp. Med. 183, 1377–1388.Gu, H., Zou, Y.R., and Rajewsky, K. (1993). Independent control of
immunoglobulin switch recombination at individual switch regions Lansford, R., Manis, J.P., Sonoda, E., Rajewsky, K., and Alt, F.W.
(1998). Ig heavy chain class switching in Rag-deficient mice. Int.evidenced through Cre-loxP-mediated gene targeting. Cell 73,
1155–1164. Immunol. 10, 325–332.
Lebecque, S., de Bouteiller, O., Arpin, C., Banchereau, J., and Liu,Hayashi, K., Nittono, R., Okamoto, N., Tsuji, S., Hara, Y., Goitsuka,
R., and Kitamura, D. (2000). The B cell-restricted adaptor BASH is Y.J. (1997). Germinal center founder cells display propensity for
apoptosis before onset of somatic mutation. J. Exp. Med. 185,required for normal development and antigen receptor-mediated
activation of B cells. Proc. Natl. Acad. Sci. USA 97, 2755–2760. 563–571.
Lederman, S., Yellin, M.J., Inghirani, G., Lee, J.L., Knowles, D.M., andHein, K., Lorenz, M., Siebenkotten, G., Petry, K., Christine, R., and
Radbruch, A. (1998). Processing of switch transcripts is required for Chess, L. (1992). Molecular interactions mediating T-B lymphocyte
collaboration in human lymphoid follicles: role of T cell-B cell activitytargeting of antibody class switch recombination. J. Exp. Med. 188,
2369–2374. molecule (5c8 antigen) and CD40 in contact-dependent help. J.
Immunol. 149, 3817–3825.Hu, H.M., O’Rourke, K., Boguski, M.S., and Dixit, V.M. (1994). A
novel RING finger protein interacts with the cytoplasmic domain of Levy, J., Espanol-Boren, T., Thomas, C., Fischer, A., Tovo, P., Bordi-
goni, P., Resnick, I., Fasth, A., Baer, M., Gomez, L., et al. (1997).CD40. J. Biol. Chem. 269, 30069–30072.
Clinical spectrum of X-linked hyper-IgM syndrome. J. Pediatr. 131,Ishida, T.K., Tojo, T., Aoki, T., Kobayashi, N., Ohishi, T., Watanabe, T.,
47–54.Yamamoto, T., and Inoue, J. (1996a). TRAF5, a novel tumor necrosis
factor receptor-associated factor family protein, mediates CD40 sig- Levy, Y., Gupta, N., Le Deist, F., Garcia, C., Fischer, A., Weill, J.C.,
and Reynaud, C.A. (1998). Defect in IgV gene somatic hypermutationnaling. Proc. Natl. Acad. Sci. USA 93, 9437–9442.
in common variable immuno-deficiency syndrome. Proc. Natl. Acad.Ishida, T., Mizushima, S., Azuma, S., Kobayashi, N., Tojo, T., Suzuki,
Sci. USA 95, 13135–13140.K., Aizawa, S., Watanabe, T., Mosialos, G., Kieff, E., et al. (1996b).
Identification of TRAF6, a novel tumor necrosis factor receptor- Liu, Y.J., Joshua, D.E., Williams, G.T., Smith, C.A., Gordon, J., and
MacLennan, I.C.M. (1989). Mechanism of antigen-driven selectionassociated factor protein that mediates signaling from an amino-
terminal domain of the CD40 cytoplasmic region. J. Biol. Chem. 271, in germinal centres. Nature 342, 929–931.
28745–28748. Liu, Y.J., Malisan, F., de Bouteillier, O., Guret, C., Lebecque, S.,
Banchereau, J., Mills, F.C., Max, E.E., and Martinez-Valdez, H.Hu, H.M., O’Rourke, K., Boguski, M.S., and Dixit, V.M. (1994). A
novel RING finger protein interacts with the cytoplasmic domain of (1996). Within germinal centers, isotype switching of immunoglobu-
lin genes occurs after the onset of somatic mutation. Immunity 4,CD40. J. Biol. Chem. 269, 30069–30072.
241–250.Jacob, J., and Kelsoe, G. (1992). In situ studies of the primary im-
mune response to (4-hydroxy-3-nitrophenyl) acetyl II. A common Lorenz, M., Jung, S., and Radbruch, A. (1995). Switch transcripts in
immunoglobulin class switching. Science 267, 1825–1828.clonal origin for periarteriolar lymphoid sheath-associated foci and
germinal centers. J. Exp. Med. 176, 679–687. Malinin, N.L., Boldin, M.P., Kovalenko, A.V., and Wallach, D. (1997).
MAP3K-related kinase involved in NF-kappa B induction by TNF,Jumaa, H., Wollscheid, B., Mitterer, M., Wienands, J., Reth, M.,
and Nielsen, P.J. (1999). Abnormal development and function of B CD95 and IL-1. Nature 385, 540–544.
lymphocytes in mice deficient for the signaling adaptor protein SLP- Manis, J.P., van der Stoep, N., Tian, M., Ferrini, R., Davidson, L.,
65. Immunity 11, 547–554. Bottaro, A., and Alt, F.W. (1998). Class switching in B cells lacking
39 immunoglobulin heavy chain. J. Exp. Med. 188, 1421–1431.Jung, S., Rajewsky, K., and Radbruch, A. (1993). Shut down of class
switch recombination by deletion of a switch region control element. Morris, A.E., Remmele, R.L., Jr., Klinke, R., Macduff, B.M., Fanslow,
Science 259, 984–987. W.C., and Armitage, R.J. (1999). Incorporation of an isoleucine zipper
motif enhances the biological activity of soluble CD40L (CD154). J.Kaartinen, M., Griffiths, G.M., Markham, A.F., and Milstein, C. (1983).
mRNA sequences define an unusually restricted IgG response to Biol. Chem. 274, 418–423.
2-phenyloxazolone and its early diversification. Nature 304, Muramatsu, M., Sankaranand, V.S., Anant, S., Sugai, M., Kinoshita,
320–323. K., Davidson, N.O., and Honjo, T. (1999). Specific expression of
activation-induced cytidine deaminase (AID), a novel member of theKinoshita, K., and Honjo, T. (2000). Unique and unprecedented
mechanisms in class switching. Curr. Opin. Immunol. 12, 195–198. RNA-editing deaminase family in germinal center B cells. J. Biol.
Chem. 274, 18470–18476.Klein, U., Rajewsky, K., and Ku¨ppers, R. (1998). Human immunoglob-
ulin (Ig)M1IgD1 peripheral blood B cells expressing the CD27 cell Muramatsu, M., Kinoshita, K., Faragasan, S., Yamada, S., Shinkai, Y.,
and Honjo, T. (2000). Class switch recombination and hypermutationsurface antigen carry somatically mutated variable region genes:
CD27 as a general marker for somatically mutated (memory) B cells. require activation-induced cytidine deaminase (AID), a potential
RNA editing enzyme. Cell, 102, this issue, 553–563.J. Exp. Med. 188, 1679–1689.
AID Gene Defects Cause HIGM2 Syndrome
575
Muto, T., Muramatsu, M., Taniwaki, M., Kinoshita, K., and Honjo, T. (1993). Replacement of germ-line epsilon promoter by gene tar-
geting alters control of immunoglobulin heavy chain class switching.(2000). Isolation, tissue distribution and chromosomal localization
of the human Activation-Induced cytidine Deaminase (hAID) gene. Proc. Natl. Acad. Sci. USA 90, 3705–3709.
Genomics, in press. Zan, H., Cerutti, A., Dramitinos, P., Schaffer, A., Li, Z., and Casali,
P. (1999). Induction of Ig somatic hypermutation and class switchingNavaratnam, N., Morrison, J.R., Bhattacharya, S., Patel, D., Funa-
in a human monoclonal IgM1 IgD1 B cell line in vitro: definition ofhashi, T., Giannoni, F., Teng, B.B., Davidson, N.O., and Scott, J.
the requirements and modalities of hypermutation. J. Immunol. 162,(1993). The p27 catalytic subunit of the apolipoprotein B mRNA
3437–3447.editing enzyme is a cytidine deaminase. J. Biol. Chem. 268, 20709–
20712. Zhang, J., Bottaro, A., Li, S., Stewart, V., and Alt, F.W. (1993). A
selective defect in IgG2b switching as a result of targeted mutationNotarangelo, L.D., Duse, M., and Ugazio, A.G. (1992). Immunodefi-
of the I gamma 2b promoter and exon. EMBO J. 12, 3529–3537.ciency with Hyper-IgM (HIM). Immunodefic. Rev. 3, 101–122.
Peters, A., and Storb, U. (1996). Somatic hypermutation of immuno-
GenBank Accession Numbersglobulin genes is linked to transcription initiation. Immunity 4, 57–65.
Rajewsky, K. (1996). Clonal selection and learning in the antibody The genomic and cDNA sequences of AID reported in this paper
system. Nature 381, 751–758. have been deposited in GenBank with accession numbers
Rathmell, J.C., Townsend, S.E., Xu, J.C., Flavell, R.A., and Goodnow, AB040430 and AB040431, respectively.
C.C. (1996). Expansion or elimination of B cells in vivo: dual role
for CD40 and Fas (CD95)-ligand modulated by the B cell antigen
receptor. Cell 87, 319–329.
Ren, C.L., Morio, T., Fu, S.M., and Geha, R.S. (1994). Signal transduc-
tion via CD40 involved activation of lyn kinase and phosphatidylinos-
iyol-3-kinase and phosphorylation of phospholipase-Cg2. J. Exp.
Med. 179, 673–680.
Revy, P., Geissmann, F., Debre, M., Fischer, A., and Durandy, A.
(1998). Normal CD40-mediated activation of monocytes and den-
dritic cells from patients with hyper-IgM syndrome due to a CD40
pathway defect in B cells. Eur. J. Immunol. 28, 3648–3654.
Rolink, A., Melchers, F., and Andersson, J. (1996). The SCID but not
the RAG-2 gene product is required for S-mu-S epsilon heavy chain
class switching. Immunity 4, 319–330.
Rothe, M., Xiong, J., Shu, H.B., Williamson, K., Goddard, A., and
Goeddel, D.V. (1996). I-TRAF is a novel TRAF-interacting protein
that regulates TRAF-mediated signal transduction. Proc. Natl. Acad.
Sci. USA 93, 8241–8246.
Rousset, F., Garcia, E., and Banchereau, J. (1991). Cytokine induced
proliferation and immunoglobulin production of human B lympho-
cytes triggered through their CD40 antigen. J. Exp. Med. 173,
705–710.
Sato, T., Irie, S., and Reed, J.C. (1995). A novel member of the TRAF
family of putative signal transducing proteins binds to the cytosolic
domain of CD40. FEBS Lett. 358, 113–118.
Scott, J. (1995). A place in the world for RNA editing. Cell 81,
833–836.
Simpson, L., and Thiemann, O.H. (1995). Sense from nonsense: RNA
editing in mitochondria of kinetoplastid protozoa and slime molds.
Cell 81, 837–840.
Song, H.Y., Regnier, C.H., Kirschning, C.J., Goeddel, D.V., and
Rothe, M. (1997). Tumor necrosis factor (TNF)-mediated kinase cas-
cades: bifurcation of nuclear factor-kappaB and c-jun N-terminal
kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2.
Proc. Natl. Acad. Sci. USA 94, 9792–9796.
Spriggs, M.K., Armitage, R.J., Strockbine, L., Clifford, K.N., Macduff,
B.M., Sato, T.A., Maliszewski, C.R., and Fanlow, W.C. (1992). Re-
combinant human CD40 ligand stimulates B cell proliferation and
immunoglobulin E secretion. J. Exp. Med. 176, 1543–1550.
Stewart, A.K., Huang, C., Stollar, B.D., and Schwartz, R.S. (1993).
High frequency representation of a single VH gene in the expressed
human B cell repertoire. J. Exp. Med. 177, 409–418.
Teng, B., Burant, C.F., and Davidson, N.O. (1993). Molecular cloning
of an apolipoprotein B messenger RNA editing protein. Science 260,
1816–1819.
Tracy, R.B., Hsieh, C.L., and Lieber, M.R. (2000). Stable RNA/DNA
hybrids in the mammalian genome: inducible intermediates in immu-
noglobulin class switch recombination. Science 288, 1058–1061.
Wiesendanger, M., Scharff, M.D., and Edelmann, W. (1998). Somatic
hypermutation, transcription, and DNA mismatch repair. Cell 94,
415–418.
Xu, L., Gorham, B., Li, S.C., Bottaro, A., Alt, F.W., and Rothman, P.
